Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2016 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about deals, orders, contracts, projects, customers, sites, programs landing now being individually bigger, broader, or longer than before. Looking at the transcript: Management discusses acquisitions, product launches, and growth. They mention acquiring Inderal LA, then later Inderal XL and InnoPran XL. But are these "same kind" of business? They are brand products. The size of acquisitions? They mention $51 million for two products, but no comparison to past deals. They talk about revenue growth, but that's overall. They mention "We have a robust pipeline of product opportunities and anticipate launching several new products in 2017." That's about number of products, not size. They talk about Corticotropin as potentially transformational, but that's a single asset, not a pattern of escalating deal size. They mention "we have access to additional sources of liquidity to fund potential future transactions" but no indication that deals are getting bigger. The question specifically asks about "successive engagements of the same kind" coming in at progressively larger size. There is no mention of average deal size increasing, or new customers starting at higher levels, or follow-on commitments being multiples. The transcript focuses on overall revenue growth, product launches, and acquisitions, but does not convey that each new deal is individually larger than the last for the same offering. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.